YiQi-HuoXue prescription ameliorates LPS-induced sepsis-associated encephalopathy via VCAM-1–mediated microglial efferocytosis

Background: The YiQi-HuoXue therapeutic approach, derived from traditional Chinese medicine, has long been used to invigorate Qi, promote blood circulation, and restore brain function in various neurological and cerebrovascular disorders. Despite its extensive clinical application, the therapeutic potential and underlying mechanisms of YiQi-HuoXue in sepsis-associated encephalopathy (SAE)-a neuroinflammatory condition with no effective treatment-remain insufficiently elucidated. Objective: To test whether YiQi-HuoXue Prescription (YQHXP) mitigates SAE and to define a mechanism centered on endothelial VCAM-1 and microglial efferocytosis. Methods: ), apoptosis, and cytokine release were measured, with pathway relevance probed using a MER proto-oncogene tyrosine kinase (MERTK) inhibitor (UNC2250) and a VCAM-1 suppressor (rutin). VCAM-1-ligand interactions were evaluated by docking and 100-ns molecular dynamics (MD) simulations, and binding was confirmed by surface plasmon resonance (SPR). Results: YQHXP improved spatial learning and novelty-directed exploration, and reduced hippocampal TNF-α, IL-6, and microglial activation. Analyses converged on a VCAM-1-linked efferocytosis axis involving complement C1q subcomponent B (C1QB)/MERTK. YQHXP downregulated VCAM-1, upregulated C1QB and MERTK in hippocampus and BV2 cells, enhanced efferocytosis, and decreased microglial apoptosis and cytokine release. Rutin or YQHXP alone increased efferocytosis; YQHXP partially restored clearance under MERTK inhibition, consistent with VCAM-1-gated regulation. Docking/MD predicted VCAM-1 engagement by several plasma-exposed prototypes, and SPR confirmed sub-millimolar binding between VCAM-1 and ginsenoside Rg1. Discussion: YQHXP may attenuate experimental SAE via VCAM-1-mediated enhancement of microglial efferocytosis, supporting VCAM-1 as a pharmacodynamic marker and efferocytosis as an actionable therapeutic axis.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-04-01
DOI
https://doi.org/10.3389/fimmu.2026.1792688
Primary Topic
Neuroinflammation and Neurodegeneration Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

YiQi-HuoXue prescription ameliorates LPS-induced sepsis-associated encephalopathy via VCAM-1–mediated microglial efferocytosis

EnFeng Song, Zheng Wang, Yun Lu, Yang Wang
Frontiers in Immunology
Neuroinflammation and Neurodegeneration Mechanisms
article

YiQi-HuoXue prescription ameliorates LPS-induced sepsis-associated encephalopathy via VCAM-1–mediated microglial efferocytosis

EnFeng Song, Zheng Wang, Yun Lu, Yang Wang
article en

Abstract

Background: The YiQi-HuoXue therapeutic approach, derived from traditional Chinese medicine, has long been used to invigorate Qi, promote blood circulation, and restore brain function in various neurological and cerebrovascular disorders. Despite its extensive clinical application, the therapeutic potential and underlying mechanisms of YiQi-HuoXue in sepsis-associated encephalopathy (SAE)-a neuroinflammatory condition with no effective treatment-remain insufficiently elucidated. Objective: To test whether YiQi-HuoXue Prescription (YQHXP) mitigates SAE and to define a mechanism centered on endothelial VCAM-1 and microglial efferocytosis. Methods: ), apoptosis, and cytokine release were measured, with pathway relevance probed using a MER proto-oncogene tyrosine kinase (MERTK) inhibitor (UNC2250) and a VCAM-1 suppressor (rutin). VCAM-1-ligand interactions were evaluated by docking and 100-ns molecular dynamics (MD) simulations, and binding was confirmed by surface plasmon resonance (SPR). Results: YQHXP improved spatial learning and novelty-directed exploration, and reduced hippocampal TNF-α, IL-6, and microglial activation. Analyses converged on a VCAM-1-linked efferocytosis axis involving complement C1q subcomponent B (C1QB)/MERTK. YQHXP downregulated VCAM-1, upregulated C1QB and MERTK in hippocampus and BV2 cells, enhanced efferocytosis, and decreased microglial apoptosis and cytokine release. Rutin or YQHXP alone increased efferocytosis; YQHXP partially restored clearance under MERTK inhibition, consistent with VCAM-1-gated regulation. Docking/MD predicted VCAM-1 engagement by several plasma-exposed prototypes, and SPR confirmed sub-millimolar binding between VCAM-1 and ginsenoside Rg1. Discussion: YQHXP may attenuate experimental SAE via VCAM-1-mediated enhancement of microglial efferocytosis, supporting VCAM-1 as a pharmacodynamic marker and efferocytosis as an actionable therapeutic axis.

Frontiers in ImmunologyVol. 17
University of Electronic Science and Technology of China (CN), Wuhan University (CN), Chengdu University (CN), Sichuan Provincial Hospital of Traditional Chinese Medicine (CN), Renmin Hospital of Wuhan University (CN), Sichuan Provincial Department of Education (CN), Second Affiliated Hospital of Chengdu University of Traditional Chinese (CN)
Good health and well-being
Openalex Percentile: Top 31%
Neuroinflammation and Neurodegeneration Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.